| Literature DB >> 26695061 |
János Tajti1, Délia Szok1, Anett Csáti1, László Vécsei2,3.
Abstract
Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.Entities:
Keywords: Antidepressants; Antiepileptics; Antihistamines; Beta-adrenergic receptor blockers; Butterbur; Calcium ion channel antagonists; Efficacy; Migraine; Onabotulinum toxin A; Pediatric; Prophylactic; Safety; Therapy; Tolerability
Mesh:
Substances:
Year: 2016 PMID: 26695061 DOI: 10.1007/s11916-015-0536-6
Source DB: PubMed Journal: Curr Pain Headache Rep ISSN: 1534-3081